Suppr超能文献

对于部分直径大于4厘米的肾细胞癌,选择性保留肾单位手术可实现出色的长期癌症控制效果。

Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm.

作者信息

Becker Frank, Siemer Stefan, Hack Markus, Humke Ulrich, Ziegler Manfred, Stöckle Michael

机构信息

Department of Urology and Paediatric Urology, Homburg, University of the Saarland, Germany.

出版信息

Eur Urol. 2006 Jun;49(6):1058-63; discussion 1063-4. doi: 10.1016/j.eururo.2006.03.003. Epub 2006 Mar 23.

Abstract

OBJECTIVES

Elective nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) < 4 cm has been accepted as alternative to radical nephrectomy (RN). However, NSS for tumours > 4 cm is controversial. We present our experiences and long-term oncologic outcome of RCC > 4 cm treated with NSS in a retrospective single-institutional analysis of 69 patients.

METHODS

Between 1975 and 2004, elective NSS was performed in 368 patients at our institution, including 69 patients with sporadic, nonmetastatic RCC > 4 cm. Overall and cancer-specific survivals were estimated using the Kaplan-Meier method.

RESULTS

Complications were seen in nine patients (13.0%). After a mean follow-up of 6.2 yr (median, 5.8 yr) seven patients (10.1%) had died, none of them of tumour-related causes. Tumour recurrence was detected in four patients (5.8%). The 5-yr overall survival probability was 94.9%. The 10-yr and 15-yr overall survival rates were both 86.7%. Cancer-specific survival was 100% after 5, 10, and 15 yr.

CONCLUSIONS

Selected patients with localized RCC even > 4 cm can be treated with elective NSS providing optimal long-term outcome. The surgeon's decision for organ-preserving surgery should depend on tumour localisation and technical feasibility rather than on tumour size.

摘要

目的

对于直径小于4cm的肾细胞癌(RCC),选择性保留肾单位手术(NSS)已被视为根治性肾切除术(RN)的替代方案。然而,对于直径大于4cm的肿瘤行NSS仍存在争议。我们通过对69例患者进行回顾性单中心分析,介绍了直径大于4cm的RCC行NSS的经验及长期肿瘤学结局。

方法

1975年至2004年间,我们机构对368例患者进行了选择性NSS,其中包括69例散发性、非转移性且直径大于4cm的RCC患者。采用Kaplan-Meier法估计总生存率和癌症特异性生存率。

结果

9例患者(13.0%)出现并发症。平均随访6.2年(中位数为5.8年)后,7例患者(10.1%)死亡,均非肿瘤相关原因。4例患者(5.8%)检测到肿瘤复发。5年总生存概率为94.9%。10年和15年总生存率均为86.7%。5年、10年和15年后癌症特异性生存率均为100%。

结论

即使是直径大于4cm的局限性RCC患者,经选择后行选择性NSS可获得最佳长期结局。外科医生决定行保肾手术应取决于肿瘤定位和技术可行性,而非肿瘤大小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验